GERMANTOWN, MD/ ACCESS Newswire/ November 10, 2026/ Precigen Inc. reported sharply improved third-quarter results late last week, driven by continuing rapid uptake of its flagship therapy PAPZIMEOS ®, as the company achieved positive cash flow a quarter ahead of schedule and posted its second consecutive profitable period. The company's third-quarter...
Precigen has the same combination that made Xeris work: a fast-growing product and a pipeline the market isn’t pricing in.
Precigen Inc (PGEN) posts $72.9 million in Q3 net product revenue, achieves back-to-back profitability, and lays out its playbook to fend off a newly approved rival in RRP.
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release third quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.
Precigen has delivered a very large share price gain over the past few years, which naturally raises a sharper question for you as an investor. Is the current US$6.66 price adequately supported by the sales the business is generating today and what the market expects it to produce next? Over the past 3 years, Precigen has produced a very large share price return, so a lot of optimism about its commercial potential is already embedded in the debate around its sales base. The group’s future...
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
Healthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Precigen's PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP. Read why PGEN stock is a strong buy.
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]
Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...
Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.
Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®. The designation reflects the adaptability and potential of the platform to address a broad ran
Precigen has seen its stock climb sharply in recent years, which naturally puts the focus on what investors are paying for each dollar of its sales. With the share price at US$7.87 at the last close, the open question is whether that level is adequately supported by the company’s current revenue base. Over the past 3 years the stock has returned about 4.6x, which puts a lot of weight on whether its sales profile can carry that kind of re-rating. For a business like Precigen, future outcomes...
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
Jeffrey B Kindler, Director, on August 26, 2026, sold 185,000 shares in Precigen (PGEN) for $1,376,4
Event driven interest in Precigen stock Fresh attention on Precigen (PGEN) follows commentary that new drug approvals and pipeline progress could support the Zacks Biomedical and Genetics industry, with Papzimeos highlighted for recurrent respiratory papillomatosis. Investors are weighing how Papzimeos commercial performance and Precigen's broader gene and cell therapy pipeline might relate to recent share price moves and the company’s current valuation profile. At a latest share price of...
Recent commentary on the Zacks Biomedical and Genetics industry highlighted Precigen’s past momentum, citing steady commercial performance from its sole marketed drug Papzimeos for recurrent respiratory papillomatosis and encouraging pipeline progress despite a challenging macro backdrop. The focus on Papzimeos as a single commercial pillar underscores both the company’s concentration risk and the importance of its broader development portfolio to diversify future revenue sources. We’ll now...
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.
This is the newest page. Registered accounts read further back.